Back to search
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase trials you may qualify forThe purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxol…
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PR…
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib…
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with tran…
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include par…
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on…
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patie…
This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in participants with myelofibrosis (MF).The dose escala…
The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (P…